We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Collaborative Cardiac Care Project (C3P)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00105664
Recruitment Status : Completed
First Posted : March 17, 2005
Last Update Posted : April 7, 2015
Information provided by (Responsible Party):

Study Description
Brief Summary:
Data from VA-funded studies and the broader literature indicate that chronic stable angina (CSA) is prevalent, under recognized, under treated and associated with reduced quality of life. There are substantial opportunities for improving care of patients with this debilitating and potentially fatal problem. Because primary care providers manage most patients with CSA, efforts to improve care must necessarily involve the primary care delivery system. C3P is composed of a set of interventions employing a Collaborative Care Team model, which has been shown to be effective in managing other chronic illnesses in the primary care setting.

Condition or disease Intervention/treatment
Myocardial Ischemia Angina Pectoris Coronary Disease Procedure: Collaborative care model Procedure: Group interventions Procedure: Facilitated consultation

Detailed Description:
Objectives of the proposed project are to: 1) ascertain whether a collaborative approach to managing CSA in primary care results in better symptom control and quality of life than routine care; 2) assess whether the practice of providers assigned to the intervention group is more consistent with national clinical practice guidelines than that of control providers; 3) assess satisfaction of both patients and providers with this approach to management; and 4) assess marginal cost-effectiveness.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 287 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Collaborative Cardiac Care Project (C3P)
Study Start Date : October 2004
Study Completion Date : July 2007
Arms and Interventions

Arm Intervention/treatment
Arm 1 Procedure: Collaborative care model Procedure: Group interventions Procedure: Facilitated consultation

Outcome Measures

Primary Outcome Measures :
  1. Symptom control, quality of life and satisfaction at one year; improved practitioner compliance with national clinical practice guidelines over the one-year intervention period

Secondary Outcome Measures :
  1. Marginal cost effectiveness during one-year study period

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Staff (MD, PA, NP) or resident (R1, R2)
  • at least 1 participating patient


  • assigned to participating provider
  • diagnosis consistent with IHD
  • 2 visits in past year
  • frequent angina symptoms (SAQ freq. score less than 70)

Exclusion Criteria:


- No participating patients


  • cognitive impairment (inability to complete questionnaires and phone interviews)
  • non-participating provider
  • life expectancy of less than 24 months
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00105664

United States, California
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California, United States, 94304-1290
United States, Colorado
VA Eastern Colorado Health Care System, Denver, CO
Denver, Colorado, United States, 80220
United States, Oregon
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States, 97239
United States, Washington
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States, 98108
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Stephan D. Fihn, MD MPH VA Puget Sound Health Care System Seattle Division, Seattle, WA
More Information

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00105664     History of Changes
Other Study ID Numbers: IHI 02-062
First Posted: March 17, 2005    Key Record Dates
Last Update Posted: April 7, 2015
Last Verified: October 2007

Keywords provided by VA Office of Research and Development:
Outcomes Assessment
Primary Health Care
Group Process

Additional relevant MeSH terms:
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Angina Pectoris
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms